Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) is a phase 2/3, randomised interventional study registered as NCT06958432 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 430 participants, started 2025-05-01 and due to reach its primary completion in 2030-12-31. Interventions recorded: Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor; Conventional Radiotherapy plus Chemotherapy and PD-1 inhibitor. Conditions listed: Rectal Cancer; Neoadjuvant Therapies; Immune Checkpoint Therapy; Radiotherapy. Primary outcome: Complete response (CR) rate; Event-Free Survival (EFS). Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.